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a b s t r a c t
The HPV-16 E6 and E6n proteins have been shown previously to be capable of regulating caspase
8 activity. We now show that the capacity of E6 to interact with caspase 8 is common to diverse HPV
types, being also seen with HPV-11 E6, HPV-18 E6 and HPV-18 E6n. Unlike most E6-interacting partners,
caspase 8 does not appear to be a major proteasomal target of E6, but instead E6 appears able to
stimulate caspase 8 activation, without affecting the overall apoptotic activity. This would appear to be
mediated in part by the ability of the HPV E6 oncoproteins to recruit active caspase 8 to the nucleus.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Human papillomaviruses (HPVs) are the causative agents of
cervical cancer (Bouvard et al., 2009). The virus encodes two
oncoproteins, E6 and E7, which directly contribute towards the
initiation of tumour formation and the maintenance of tumour
development (Androphy et al., 1987; Banks et al., 1987; Smotkin
and Wettstein, 1986). Loss of expression or inhibition of E6/E7
function in cells derived from cervical tumours results in a
cessation of transformed cell growth and induction of either
senescence or apoptosis (Butz et al., 1996, 2003; Jabbar et al.,
2012; von Knebel Doeberitz et al., 1992). Therefore both E6 and E7
represent excellent targets for therapeutic intervention in HPV-
associated malignancy. Both E6 and E7 exert their transforming
activities through multiple mechanisms. In the case of E7, this
involves inactivation of essential regulators of cell cycle control, of
which the pRb family of pocket proteins are the most well-deﬁned
(McLaughlin-Drubin and Munger, 2009). The E6-induced inactiva-
tion of p53 and of PDZ domain-containing targets is also believed
to play critical roles in the ability of the virus to induce trans-
formed phenotypes (Banks et al., 2012; Moody and Laimins, 2010).
However additional mechanisms are also likely to be involved, as
evidenced by the broad array of novel interacting partners recently
demonstrated in a variety of proteomic analyses of both the E6 and
E7 oncoproteins from multiple HPV types (Rozenblatt-Rosen et al.,
2012; White et al., 2012).
Although there are close to 200 different HPV types (zur
Hausen, 2009), only a small subset of these, the so-called high-
risk types, cause cervical cancer (Munoz et al., 2003). A great deal
of effort has been expended in trying to identify the unique
characteristics of these high-risk viruses that might be responsible
for tumour development. One such potentially relevant feature of
this group of viruses is the alternative splicing of the E6 ORF,
which generates multiple short forms of the E6 proteins, termed
E6n (Smotkin et al., 1989). In the case of HPV-18 E6n, only one such
isoform is produced, whilst in the case of HPV-16 E6n at least three
such isoforms have been reported (Doorbar et al., 1990;
Roggenbuck et al., 1991). The functions of E6n are still a matter
of intense debate. In some cases they appear to be able to
negatively regulate the activity of the full-length E6 proteins
(Pim and Banks, 1999; Pim et al., 1997), whilst in others they
seem to have intrinsic functions of their own, and potentially
modulate a variety of different signal transduction pathways (Pim
et al., 2009). A series of recent studies provided indications that
the HPV-16 E6 and E6n proteins can differentially affect caspase
activity, an effect related to their ability to interact with caspase
8 and, in the case of full length E6, target it for degradation
(Filippova et al., 2007; Tungteakkhun et al., 2010). These studies
focused on the effects of E6 and E6n on cell survival and apoptosis
induction pathways; however recent studies have also shown that
caspase activation is an important aspect of the normal viral life
cycle, appearing to be essential for the later stages of the viral life
cycle in differentiating keratinocytes (Moody et al., 2007). We have
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therefore been interested in investigating how conserved was the
ability of different HPV E6 proteins, and their alternatively spliced
isoforms, to interact with and modulate caspase 8 activity.
Results
E6 from different HPV interact with pro-caspase 8 and DED in vitro
Previous studies had shown that HPV-16 E6n, and to a much
lesser extent the full length HPV-16 E6, could interact with caspase
8 through the death effector domain (DED) (Tungteakkhun et al.,
2010). Since modulation of caspase activation appears important
for the viral life cycle (Moody et al., 2007), we were interested in
determining whether the E6 proteins from other HPV types could
also associate with caspase 8 in a similar manner. To do this, we
performed a series of GST pull-down assays using puriﬁed GST
fusion proteins of HPV-11 E6, HPV-16 E6, HPV-18 E6 and the two
corresponding E6n proteins. Full-length caspase 8 was in vitro
translated and radiolabelled with 35S-methionine, and then incu-
bated with the GST fusion proteins. Interaction assays were done
at 4 1C, to reﬂect the conditions used in previous studies (Filippova
et al., 2007), and also at room temperature. Following extensive
washing the bound proteins were analyzed by SDS PAGE and
autoradiography. The results in Fig. 1A demonstrate that all the E6
proteins analyzed showed a similar capacity to interact with the
caspase 8, although HPV-18 E6n appeared to interact somewhat
more strongly. Surprisingly, and in contrast to previous studies, we
also observed association between HPV-11 E6 and caspase 8,
although in all cases interaction was signiﬁcantly stronger at room
temperature than at 4 1C, demonstrating that the ability of E6 to
bind to caspase 8 is cold sensitive. To extend these analyses to
determine whether the site of interaction was mediated via the
DED, we repeated the assays using the isolated in vitro translated
radiolabeled caspase 8 DED. The results in Fig. 1B again demon-
strate a similar level of interaction between the different E6
proteins and the DED, which is, again, cold sensitive. Again, high
levels of interaction are seen with both the full length and E6n
proteins, as well as with HPV-11 E6.
HPV-18 E6n interaction with DED is carboxy terminal domain
dependent
Previous studies had shown a signiﬁcant difference in the
ability of HPV-16 E6n and HPV-16 E6 to interact with caspase 8
(Filippova et al., 2007). In our analysis we noticed a slight increase
in the capacity of HPV-18 E6n to interact with caspase 8 compared
with the full length E6 protein. To investigate the mechanism by
Fig. 1. Different HPV E6 proteins interact with the caspase 8 DED. The different HPV E6 fusion proteins were puriﬁed and incubated with in vitro translated and radiolabelled
full-length caspase 8 (Panels A and C) or the isolated DED (Panel B) at either room temperature (left hand panels) or at 4 1C (right hand panels). After extensive washing the
bound proteins were analyzed by SDS PAGE and autoradiography. Arrows highlight the bound caspase 8 or DED whilst the lower section in each Panel shows the Coomassie
stained gel to show similar levels of GST fusion protein expression. The 20% inputs of the caspase 8 and DED are also shown.
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which this could occur, we repeated the assay using wild type E6n
plus a mutant where the carboxy terminal 8 unique amino acids
were deleted. As can be seen from Fig. 1C, HPV-18 E6n does
interact slightly more efﬁciently with caspase 8 compared with the
full length E6 protein at both room temperature and 4 1C.
Furthermore, this increased association would appear to require
the amino acid residues lying within the unique carboxy terminal
stretch of E6n. These results demonstrate that interaction between
E6 and caspase 8 is conserved across both low- and high-risk HPV
types, and, in the case of HPV-18 E6n, involves sequences that are
unique to the carboxy terminal region of the protein.
E6 induces caspase 8 activation
In an extensive series of in vitro degradation assays, none of the
above E6 proteins were found to have any effect upon the stability
of caspase 8 (data not shown). Therefore we proceeded to
investigate the effects of E6 upon the levels of caspase 8 expression
in vivo. HEK293 cells were transfected with a caspase 8 expression
plasmid, together with either HA-tagged HPV-18, HPV-16 or HPV-11
E6 expression plasmids. After 24 h the cells were harvested and the
pattern of caspase 8 activation monitored by Western blotting using
anti-caspase 8 antibody. As can be seen from Fig. 2A, the different
E6 proteins slightly reduced the total levels of full-length (p57)
caspase 8 expression. However, the amount of cleaved active (p18)
caspase 8 increased signiﬁcantly, in the presence of the full length
HPV-16 and HPV-18 E6 proteins, as well as with HPV-11 E6. In
addition, a modest increase in caspase 8 activation was also
observed with HPV-18 E6n. These results indicate that, although
E6 does not signiﬁcantly affect total caspase 8 levels in transient
transfection experiments, it can nonetheless affect the degree to
which caspase 8 is activated.
E6 binding to pro-caspase 8 does not induce apoptosis
Caspase 8 is the initiator caspase in the induction of the
apoptotic cascade (McIlwain et al., 2013). Therefore we performed
a series of assays to investigate whether the levels of increased
caspase 8 activation seen in the presence of E6 was sufﬁcient to
increase the levels of apoptosis induced by caspase 8 overexpres-
sion. Cells were transfected with caspase 8, in the presence and
absence of HPV-18 E6 and HPV-18 E6n expression plasmids, and
after 24 h the levels of apoptosis were assessed by Annexin V
binding and FACS analysis. As can be seen from Fig. 2B, E6
expression had a minimal effect on the levels of apoptosis induced
by caspase 8, indicating that the increase in caspase 8 activation
induced by E6 in Fig. 2A does not result in increased levels of
apoptosis.
E6 induces caspase 8 nuclear translocation
Previous studies have shown that caspase activation is an
important step in the HPV life cycle (Moody et al., 2007; Terenzi
et al., 2008; Yu et al., 2007). Caspases are found primarily in the
cytoplasm (Zhivotovsky et al., 1999) whilst E6 oncoproteins are
expressed throughout the cell. We were therefore interested in
determining whether E6 could in any way modulate the localiza-
tion of caspase 8 within the cell. To do this, U2OS cells were
transfected with a caspase 8 expression plasmid in the presence
and absence of the HA-tagged HPV E6 expression plasmids. After
24 h, the cells were ﬁxed and analyzed for the presence of HA-
tagged E6 proteins and the co-transfected caspase 8 by immuno-
ﬂuorescence and microscopy. The results in Fig. 3 demonstrate
that E6 has a diffused distribution, with both nuclear and cyto-
plasmic patterns of expression, similar to that reported previously
(Guccione et al., 2004; Vaeteewoottacharn et al., 2005). Caspase 8,
when transfected alone, is also predominantly found within the
cytoplasm (Fig. 3A and Supplementary Fig. 1A). In contrast, when
caspase 8 is co-expressed with either HPV-18 E6, HPV-16 E6 or
HPV-11 E6 there is a signiﬁcant degree of co-localization (Fig. 3B
and Supplementary Fig. 1B and 1C) between E6 and caspase 8.
In addition in cells where E6 nuclear localization is apparent, there
is a corresponding increase in the levels of nuclear caspase
8 expression. Similar results are also obtained with HPV-18 E6n,
where, again, there is a signiﬁcant degree of co-localization with
caspase 8, and a signiﬁcant re-localization of caspase 8 to the
nucleus. These results demonstrate that caspase 8 activation
induced by HPV E6 is accompanied by an increase in the amount
of caspase 8 found within the nucleus.
The presence of caspase 8 in the nucleus of HeLa cells is E6 dependent
In order to determine whether the pattern of caspase 8 was
similarly affected by endogenous HPV-18 E6, HeLa cells were
transfected with siRNA against luciferase as a control or against
HPV-18E6/E7. After 72 h the cells were extracted into cytoplasmic,
membrane, nuclear and cytoskeletal pools, and the pattern of
caspase 8 expression ascertained by Western blotting. The results
obtained are shown in Fig. 4A and demonstrate strong accumula-
tion of p53 in the nucleus of cells transfected with siE6/E7. In the
case of active caspase 8, there is a clear signal present within the
Fig. 2. HPV E6 proteins promote activation of caspase 8. Panel A. HEK293 cells were
transfected with a caspase 8 expression plasmid either alone or together with the
different E6 expression plasmids as indicated. After 24 h the cells were harvested
and the levels of caspase 8 expression ascertained by Western blot analysis.
Indicated is the full-length form of caspase 8 (p44) and the active cleaved form
(p18). Also shown is the transfection and loading efﬁciency control of β-gal. Panel B.
HEK293 cells were transfected with caspase 8 either alone or with HPV-18 E6
expression plasmids, as indicated, and after 24 h the cells were harvested and levels
of apoptosis ascertained by Annexin V staining and FACS analysis. The results show
percentage apoptosis from three separate experiments together with the standard
deviations.
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nuclear fraction, and this decreases signiﬁcantly upon siE6/E7
transfection.
We also performed immunoﬂuorescence analysis of the pat-
terns of caspase 8 expression in HeLa cells following siRNA
ablation of E6/E7 expression. As can be seen from Fig. 4B, caspase
8 displays a predominantly cytoplasmic distribution in HPV
negative HaCaT cells, whilst in control siRNA transfected HeLa
cells caspase 8 has a signiﬁcant proportion of nuclear localization.
However, following transfection with siRNA E6/E7 there is a
signiﬁcant accumulation of cytoplasmic caspase 8. These results
demonstrate that there are increased levels of nuclear caspase 8 in
cells expressing HPV E6 oncoproteins.
Discussion
The ability of the high-risk HPV E6 oncoproteins to contribute
towards the development of cervical cancer requires multiple
functions, a number of which are likely to be absent from the
low risk HPV E6 oncoproteins (Rozenblatt-Rosen et al., 2012;
White et al., 2012). The capacity of high-risk HPV E6 oncoproteins
to exist as an alternatively spliced shorter isoform termed E6n is
one such unique feature of the high-risk HPV types (Doorbar et al.,
1990; Smotkin et al., 1989). Although the E6n proteins do not
appear to play a major role in the capacity of these HPV types to
bring about cell immortalization or transformation (Sedman et al.,
1991), they do nonetheless have a number of other intriguing
activities. One of these is their ability, in conjunction with the full-
length E6 proteins, to interact with and potentially modulate, the
activity of caspase 8 (Filippova et al., 2007; Tungteakkhun et al.,
2010). In the case of HPV-16, E6n appeared to enhance caspase 8-
induced apoptosis, whilst the full-length E6 protein appeared
capable of directing caspase 8 degradation. Thus, changes in the
ratios of expression of the two forms of E6 could be expected to
play a major role in viral pathogenesis. In the present study, we
have found that interaction with caspase 8 is common to E6
Fig. 3. HPV E6 modiﬁes the subcellular distribution of caspase 8. U2OS cells were transfected with caspase 8 or the different E6 expression plasmids, either alone (Panel A) or
in combination (Panel B) as indicated. After 24 h the cells were ﬁxed and the patterns of caspase 8 expression ascertained by immunoﬂuorescence analysis using anti-caspase
8 antibody and rhodamine-conjugated anti-mouse antibody (red), and HPV E6 detected by immunoﬂuorescence analysis using anti-HA antibody and anti-rabbit Alexa 414
(green). Note the largely cytoplasmic distribution of caspase 8 and the nuclear/cytoplasmic distribution of the E6 proteins. Upon co-expression, there is marked
co-localization of both proteins throughout the cell but an increase of caspase 8 in the nucleus in cells where E6 also displays nuclear accumulation.
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proteins of both high and low risk types, and that one conse-
quence of this association is the stimulation of caspase 8 activity
and concomitant re-localization to the nucleus.
The ability of different HPV E6 oncoproteins to interact with
caspase 8 appears to be quite highly conserved. Using simple GST
pull-down assays we found that high risk HPV-16 and HPV-18 E6
proteins, as well as low risk HPV-11 E6, could all interact with
caspase 8. This interaction also seemed to involve a similar mode
of recognition, with interaction appearing to be mediated via the
caspase 8 DED. Interestingly, E6 proteins appear to interact more
strongly with the isolated DED than with the full-length caspase 8.
The reasons for this are unclear but could involve conformational
changes in the DED once it is removed from the activated caspase,
or be indirect and be a reﬂection of the tendency for an isolated
DED to aggregate (Mielgo et al., 2009), and thereby increase the
amount complexed with E6. Further studies will be required to
Fig. 4. HPV-18 E6 induces active caspase 8 expression in the nucleus of HeLa cells. Panel A. Cells were transfected with siRNA luciferase (L) or siRNA E6/E7 (E6) and after 72 h
the cells were harvested and fractionated into cytoplasmic (I), membrane (II), nuclear (III) and cytoskeletal pools (IV). The fractions were then subjected to Western blot
analysis for caspase 8 (p57 full length and active p18) and p53. Markers for loading and fraction integrity were vimentin, tubulin, p84 and transferrin receptor (TR). Panel B.
HeLa cells were transfected with siRNA luciferase (si luc) or siRNA E6/E7 (si E6) and after 72 h cells were ﬁxed and stained for p53 and caspase 8. HaCaT cells were included
for comparison. Note the strong increase in nuclear p53 following E6/E7 ablation and the corresponding increase in cytoplasmic caspase 8, which is indicated by the arrows.
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investigate these possibilities. Furthermore, in all cases the inter-
action between E6 and caspase 8 was cold sensitive, with only
minimal levels of association detectable at 4 1C. Interestingly, we
did not detect much difference between the abilities of HPV-16 E6
and HPV-16 E6n to interact with caspase 8, although HPV-18 E6n
showed a modest but signiﬁcantly increased potential to associate
with caspase 8 compared with full length HPV-18 E6. Interestingly,
this increased capacity to bind to caspase 8 appeared to be
mediated through the unique carboxy terminal 8 amino acids of
HPV-18 E6n protein.
A large number of HPV E6 substrates are directed for degrada-
tion at the 26S proteasome (Scheffner et al., 1993; for review see
Banks et al., 2003), although in the case of caspase 8, E6 has little
effect on the total levels of caspase 8 expression in cell. However
the E6 proteins, and to a lesser extent E6n, all seem capable of
stimulating caspase 8 cleavage to the active form of the enzyme.
This would initially seem counterintuitive, as it might suggest that
E6 was capable of stimulating caspase 8-driven apoptosis. How-
ever this does not appear to be the case, and this is most likely due
in part to the ability of E6 to alter the subcellular distribution of
caspase 8. Thus, caspase 8 when expressed alone is found
primarily within the cytoplasm, whilst in the presence of E6 and
E6n there is a marked increase in the amount of caspase 8 found in
the nucleus. This occurs when E6 proteins are overexpressed and
co-transfected with caspase 8, but is also observed with endogen-
ous caspase 8 in HeLa cells, where there are high levels of nuclear
caspase 8 which becomes much more cytoplasmic following siRNA
ablation of E6/E7 expression. This nuclear accumulation of caspase
8 is in agreement with previous studies that reported increased
levels of caspase 8 in the nucleus of HPV positive tumour cell lines
and cervical cancers (Arechaga-Ocampo et al., 2008). Our results
now indicate that this is most likely due to the activity of the E6
oncoprotein. These results suggest that E6 most likely recruits
caspase 8 to the nucleus to perform functions that are beneﬁcial
either for the viral life cycle, or in the maintenance of cell
proliferation in E6 transformed cells. What these activities are
remains unclear, but could involve modulation of apoptotic path-
ways depending upon the levels of E6 expression (Filippova et al.,
2007), or the targeting of substrates that would not normally be
recognized by the caspase in these particular cellular locations.
One such candidate would be the viral E1 protein, which is cleaved
by caspases as part of the normal viral life cycle (Moody et al.,
2007) and it will now be of interest to determine whether E6 has
any potential role in this activity.
Materials and methods
Cells and transfections
Hek-293, HeLa, U2-OS and HaCaT cells were maintained in
Dulbecco's modiﬁed Eagle medium (DMEM) supplemented with
10% fetal bovine serum (FBS). Transfections were done by the
calcium phosphate method or by FuGENEs HD Transfection
Reagent (Promega) according to the manufacturer's instructions.
Plasmids
HA-tagged HPV E6 expression plasmids were described pre-
viously (Thomas et al., 2013). Pro-caspase 8 expression plasmid
was obtained by cloning the pro-caspase 8 sequence into the
pcDNA3 vector. The pCA-DED construct was obtained by cloning
the coding sequence of Pro-caspase 8 death effector domain into
the pCA backbone using standard PCR (BamHI and EcoRI sites).
The products were veriﬁed by sequencing.
GST-fusion proteins puriﬁcation
GST-fusion proteins production and puriﬁcation were described
previously (Pim et al., 1997).
In vitro translation and in vitro binding assays
An amount of 1 μg pro-caspase 8 or DED expressing plasmid
was in vitro transcribed and translated using the TNT T7 Coupled
Reticulocyte Lysate Systems (Promega) employing [35S]-methio-
nine according to the manufacturer's instructions. For the in vitro
binding assays equal amounts of the different E6 GST-fusion
proteins were incubated with either in vitro translated pro-
caspase 8 or in vitro translated DED in PBS at 4 degrees or room
temperature for 90 min. After extensive washing with 0.2% NP-40/
PBS the bound proteins were analyzed by SDS-PAGE and auto-
radiography. GST-fusion proteins amount was analyzed by Coo-
massie staining.
Immunoﬂuorescence and cell imaging
About 24 h after transfection U2-OS cells were ﬁxed in 3%
paraformaldehyde in PBS for 20 min and permeabilized with 0.1%
Triton-X100, the cells were then incubated for 2 h at 37 1C with
polyclonal anti-HA probe (Santa Cruz biotechnology), monoclonal
anti caspase 8 (1C12, Cell Signalling) either alone or in combina-
tion, washed extensively with PBS, and incubated with anti-mouse
or anti-rabbit conjugated to ﬂuorescein or rhodamine (Molecular
Probes) at 37 1C. Slides were washed and mounted in Vectashield
mounting medium (Vector Laboratories). HeLa and HaCaT cells
were processed in the same manner 72 h post siRNA transfection
and were incubated with anti p53 (Santa Cruz) and anti-caspase
8 antibody (IC12, Cell Signalling). Slides were analyzed with either
a Leica DMLB ﬂuorescence microscope with a Leica photo camera
(A01M871016) or a Zeiss LSM 510 confocal microscope with two
lasers giving excitation lines at 480 and 510 nm. The data were
collected with a 60 objective oil immersion lens.
siRNA silencing and fractionation experiments
HeLa cells were seeded in 6 cm diameter dishes and main-
tained for 24 h to allow attachment, then cells were transfected
with siRNA (Dharmacon) against E6/E7 (50CAUUUACCAG
CCCGACGAG) and Luciferase as a control, using the Lipofecta-
mines RNAiMAX Transfection Reagent (Invitrogen) according to
the manufacturer's instructions. About 72 h after silencing, cells
were harvested and protein extracted using the sub-cellular
proteome extraction kit (Calbiochem) according to the manufac-
ture's instructions, protein levels were evaluated by Western blot.
Western blotting and antibodies
After 24 h post transfection, cells were washed and directly
lysed in sample loading buffer to generate a total cell extract
which was analyzed by SDS-PAGE and Western blotting onto a
0.22 μm nitrocellulose membrane (Schleicher and Schuell). Mem-
branes were blocked at 37 1C in 7% milk/0.1% Tween 20/PBS for
1 h, followed by incubation with the appropriate primary antibody
diluted in 5% milk/0.1% Tween 20/PBS. After washing three times
with 0.1% Tween 20/PBS membranes were incubated with HRP-
conjugated anti mouse (DAKO) in 5% milk/0.1% Tween 20/PBS for
1 h. Blots were developed using Amersham ECL reagents according
to manufacturer´s instructions. Primary antibodies were used
as follows: anti-Caspase 8 (1C12) (Cell signalling) at 1:1000
which recognizes both the active and inactive forms of the
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enzyme, anti-HA (Roche) at 1/1000 and anti-β-galactosidase
(Promega) at 1/5000, anti p53 (Santa Cruz) at 1:1000.
Annexin V assay
HEK293 cells were seeded in a 6 cm diameter dish and
transfected with a plasmid expressing Procaspase 8, either alone
or in combination with HPV-18 E6 and E6n plasmids. After 24 h the
cells were washed and trypsinized gently. They were then washed
once in DMEM/10%FBS and once in PBS. The amount of apoptosis
was then determined by incubating the cells with Annexin V-FITC
using the Annexin-V-FLUOS Staining kit (Roche) according to the
manufacturer's instructions. The cells were then analysed using a
FACSCalibur ﬂuorescence-activated cell sorter (Becton Dickinson).
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